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ORIGINAL ARTICLE
Downregulation of the serum response factor/miR-1
axis in the quadriceps of patients with COPD
Amy Lewis,1 Joanna Riddoch-Contreras,1 Samantha A Natanek,2 Anna Donaldson,1,2
William D-C Man,2 John Moxham,3 Nicholas S Hopkinson,2
Michael I Polkey,2 Paul R Kemp1
ABSTRACT
Rationale Muscle atrophy confers a poor prognosis in
patients with chronic obstructive pulmonary disease
(COPD), yet the molecular pathways responsible are
poorly characterised. Muscle-specific microRNAs and
serum response factor (SRF) are important regulators of
muscle phenotype that contribute to a feedback system
to regulate muscle gene expression. The role of these
factors in the skeletal muscle dysfunction that
accompanies COPD is unknown.
Methods 31 patients with COPD and 14 healthy
age-matched controls underwent lung and quadriceps
function assessments, measurement of daily activity and
a percutaneous quadriceps muscle biopsy. The
expression of muscle-specific microRNAs, myosin heavy
chains and components of the serum response factor
signalling pathway were determined by qPCR.
Results A reduction in expression of miR-1 (2.5-fold,
p¼0.01) and the myocardin-related transcription factors
(MRTFs) A and B was observed in patients compared
with controls (MRTF-A mRNA: twofold, p¼0.028;
MRTF-B mRNA: fourfold, p¼0.011). miR-1 expression
was associated with smoking history, lung function,
fat-free mass index, 6 min walk distance and percentage
of type 1 fibres. miR-133 and miR-206 were negatively
correlated with daily physical activity. Insulin-like growth
factor 1 mRNA was increased in the patients and miR-1
was negatively correlated with phosphorylation of the
kinase Akt. Furthermore, the protein levels of histone
deacetylase 4, another miR-1 target, were increased in
the patients.
Conclusions Downregulation of the activity of the
MRTF-SRF axis and the expression of muscle-specific
microRNAs, particularly miR-1, may contribute to
COPD-associated skeletal muscle dysfunction.
INTRODUCTION
Skeletal muscle dysfunction in the locomotor
muscles is an important systemic complication of
chronic obstructive pulmonary disease (COPD).
Quadriceps weakness and wasting predict mortality
among patients with moderate to severe COPD
independently of lung function1 2 and are common
complications.3 Characteristically, the vastus later-
alis of patients with COPD exhibits a shift towards
a predominance of type IIA ﬁbres and an increase in
the proportion of type IIX ﬁbres associated with
a marked reduction in exercise capacity.4 5 In addi-
tion to these changes, ﬁbre atrophy occurs and is
particularly marked in type IIX ﬁbres. However, the
mechanisms that control these phenotypic changes
have not been fully deﬁned.
Recent data have implicated microRNAs
(miRNAs, small non-coding RNAs that reduce
mRNA half-life and translation) in the regulation of
the skeletal muscle phenotype.6 Several miRNAs
are highly expressed in skeletal muscle and regulate
muscle phenotype. miR-1 and miR-206 promote
myotube formation7 and miR-206 is associated
with regeneration after nerve injury.8 Genetic
knockout of miR-499 or miR208-b reduces the
proportion of type I ﬁbres whereas overexpression
of miR-499 increases type I ﬁbres and endurance in
mice.9 10 Conversely, miR-133 expression inhibits
myotube formation and promotes proliferation.11
Analysis of miRNA expression in primary skel-
etal myopathies identiﬁed changes in miRNAs that
target conserved pathways, but the expression of
individual miRNAs varied.12 Similarly, the proﬁle of
miRNAs is altered in the skeletal muscle of patients
with insulin resistance.13 miRNA proﬁles are also
markedly affected by activity, and studies in
humans have shown altered miRNA proﬁles asso-
ciated with endurance exercise training.14 As inac-
tivity may be a major contributor to skeletal
muscle dysfunction in COPD, changes in miRNA
expression associated with inactivity may
contribute to the phenotype. Studies of inactivity
resulting from denervation,15 nerve entrapment16
or space ﬂight17 all show initial reductions in
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miR-1, but whether miR-1 levels remain suppressed varies.
Interestingly, miR-1 did not change in response to resistance
training in humans but there was altered expression of miRs
associated with the mTOR pathway.18
The myocardin-related transcription factor (MRTF)-serum
response factor (SRF) axis regulates the expression of miR-119
and other muscle-speciﬁc miRNAs.20 Changes in the expression
and localisation of SRF and the SRF co-activators, MRTF-A and
MRTF-B, in response to physical activity and ageing have all
been reported.21e23 In addition to miRNA expression, MRTF/
SRF activity is important in regulating MHC expression. SRF
activity is more important in activating expression of MHCI
than MHCIIa and MHCIIx, implying a role for SRF in ﬁbre-type
control.24 The miRNAs feed back to regulate MRTF/SRF and
other factors that control muscle cell phenotype such as
myocyte enhancer factor-2 (MEF-2), and proliferation including
insulin-like growth factor 1 (IGF-1)25 and the myostatin
signalling pathway.26 27 Together these MRTF/SRF-miRNA
interactions provide the system shown in ﬁgure 1.
We hypothesised that reduced physical activity commonly
observed in patients with COPD would suppress SRF activity
and reduce expression of miR-1 and other SRF-dependent
miRNAs along with altered expression of miRNA targets in
comparison with healthy controls. We therefore analysed
muscle-speciﬁc miRNA expression, the expression of miR-145
(an miRNA associated with SRF activity in smooth muscle) and
miR-181 (an miRNA altered by activity but not known to be
SRF-dependent28) along with the expression of components of
the SRF pathway in quadriceps biopsies from patients with
COPD and age-matched controls. Some of the results presented
here have been reported in abstract form.29
METHODS
Subjects
Thirty-one patients with COPD according to the Global
Initiative in Obstructive Lung Disease guidelines 200430 were
enrolled from clinics at the Royal Brompton Hospital. Fourteen
healthy age-matched controls were recruited by advertisement.
Patient exclusion criteria and ethical approval are detailed in the
online supplement.
Physiological measurements
General assessment
Lung volume, carbon monoxide transfer, blood gas tension and
fat-free mass index (FFMI) were measured as described in the
online supplement.
Muscle assessments
Quadriceps strength was determined by measuring maximal
voluntary contraction (MVC) and unpotentiated twitch
quadriceps force (TwQ). Exercise performance was measured
using a 6 min walk (6MW) test and daily physical activity
was measured using a tri-axial accelerometer. Detailed
descriptions of the physiological methods are given in the
online supplement.
Assessment of mRNA, miRNA and protein levels
Messenger RNA was extracted and quantiﬁed as described
previously31 and detailed in the online supplement. MicroRNA
expression was analysed in trizol extracted RNA using the
Ncode SYBR green miRNA-qRT-PCR kit (Invitrogen, Paisley,
UK) as detailed in the online supplement. Protein was analysed
by luminex or western blotting as described in the online
supplement. The amount of material available did not allow us
to measure all values in all subjects.
Assessment of MRTF activity
The activity of MRTFs on the miR-1 promoters was determined
as described in the online supplement.
Immunofluorescence analysis
Fibre size, ﬁbre proportion and SRF localisation were determined
by immunoﬂuorescence as described in the online supplement.
Statistical analysis
Unsupervised principal components analysis (PCA) and unsu-
pervised hierarchical clustering were performed in Aabel
(Gigawiz). The variables for hierarchical clustering were scaled
to unit variance and distances calculated based on correlation
coefﬁcient similarity. Groups were deﬁned based on centroid
linkage. Log transformation of the miRNA data produced
a normal distribution for all the miRNAs. Correlation analysis
was performed using the Pearson correlation coefﬁcient. To
interpret the correlation data, p<0.05 was taken as an indicator
of association to allow us to investigate likely relationships
within the data, but none of the relationships were signiﬁcant if
applying a Bonferroni correction.
Differences between patients and controls were calculated by
the Student t test for normally distributed data and by the
ManneWhitney U test for data that did not ﬁt a normal
distribution. The test used for each analysis is denoted by T
(t-test) and MW (ManneWhitney U) in parentheses. The
statistical signiﬁcance of differences was taken at p<0.05.
RESULTS
Patient characteristics and muscle phenotype
As expected, the patients had signiﬁcant lung function impair-
ment and reduced arterial blood oxygen tensions, consistent
with a diagnosis of COPD. However, there was no signiﬁcant
difference in age, weight, body mass index (BMI) or arterial
blood carbon dioxide tensions between groups and the groups
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miR-133/145miR-1/ 206
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Myostatin
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SRF
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Figure 1 Relationships between miRNAs and selected target genes in
muscle. The relationship between miRNAs and the RNAs that encode
proteins is shown. miRNA targets are either predicted using targetscan
(http://www.targetscan.org/) or verified by experiment. HDAC4, histone
deacetylase 4; IGF-1, insulin-like growth factor 1; MRTF, myocardin-
related transcription factor; SRF, serum response factor; Act IIB
receptor, activin type IIB receptor.
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were matched for gender (p¼0.74, Fisher exact test). Patients
had a signiﬁcantly reduced FFMI, quadriceps force and loco-
motion time compared with controls (table 1).
The patients had a marked difference in the size and propor-
tion of muscle ﬁbres compared with the controls (see ﬁgure S1 in
online supplement). The proportion of type I ﬁbres in the
patients was reduced (from a median of 52 (IQR 39e62) to 25
(IQR 17e30)) and the proportion of type II ﬁbres was increased
(from mean6SD 47614 to 69615, table 1). The proportion of
hybrid type I/type II ﬁbres was also increased in patients (from
a median of 1.5 (IQR 0e3) to 3 (IQR 0e11), table 1). The ﬁbres
of the patients were smaller than those of the controls with
a signiﬁcant reduction in the size of the type I and type IIX
ﬁbres (table 1).
Patients had reduced MHCI mRNA compared with controls
(table 1 and ﬁgure S2 in online supplement). MHCI mRNA was
directly correlated with forced expiratory volume in 1 s (FEV1)
percentage predicted and inversely correlated with smoking
history across both patients and controls (see ﬁgure S2 in online
supplement). MHCIIa expression was not correlated with
smoking history or FEV1 (not shown). MHCI mRNA was
positively correlated with exercise performance (6MW, ﬁgure S3
in online supplement) but was not associated with strength.
MHCIIa was inversely correlated with 6MW (ﬁgure S3 in online
supplement) across all data as well as within the patient group
alone, but also showed no association with strength. There was
no signiﬁcant difference in a-actin expression between the
groups (data not shown).
miRNA expression in quadriceps of patients with COPD
Multivariate statistical analyses (eg, hierarchical clustering and
PCA) offer a powerful unsupervised approach for the identiﬁ-
cation of structure and relationships between samples, allowing
for the visualisation of natural groupings in data. Hierarchical
Table 1 Clinical characteristics of study subjects
Controls (n[14) COPD (n[31)
Significance
(p value)
Sex (F:M) 6:8 11:21
Age 6868 6567 0.192 (T)
Height (cm) 17168 16969 >0.5 (T)
Weight (kg) 79.8618.4 70.9616.5 0.114 (T)
BMI (kg/m2) 26.964.5 24.564.7 0.109 (T)
FFMI (kg/m2) 17.862.3 15.762.2 0.006 (T)
Pack-years* 4.1 (0e10) 45 (34e69) <0.001 (MW)
FEV1 (% pred)* 110 (103.6e112.6) 32 (25.1e47.1) <0.001 (MW)
RV/TLC (%) 37.164.7 58.669.9 <0.001 (T)
TLCO (% pred)* 86 (82.5e91.8) 33 (26.2e52.2) <0.001 (MW)
PaCO2 (kPa)* 5.33 (4.80e5.42) 5.18 (4.96e5.74) >0.5 (MW)
PaO2 (kPa) 10.3761.55 9.2561.34 0.017 (T)
6MW (m) 623689 3786134 <0.001 (T)
6MW (% pred) 125615 72624 <0.001 (T)
Locomotion
time (min/12 h)*
86 (61e122) 45.5 (23e81) 0.006 (MW)
Mt (%)* 20.667.2 15.766.2 0.03 (T)
MI (m/s2)* 2.1 (1.7e2.4) 1.6 (1.4e2.0) 0.017 (MW)
SGRQ* 5 (1e8) 52 (41e61) <0.001 (MW)
Best MVC 36.8467.78 29.2169.11 0.009 (T)
Best TwQ 9.5863.04 7.8962.41 0.077 (T)
MVC/BMI 1.460.3 1.260.3 0.075 (T)
Quadriceps
endurance T80(s)*
110 (70e160) 80 (60e105) 0.121 (MW)
MHCI mRNA (AU)* 28.0 (19.2e39.9) 7.0 (4.8e14.0) <0.001 (MW)
MHCIIA mRNA (AU)* 1.5 (0.8e2.2) 2.6 (1.3e3.6) 0.105 (MW
Type I CSA (mm2) 578661371 490961327 0.048 (T)
Type IIA CSA (mm2)* 4593.5 (29466105) 3784 (29644615) 0.141 (MW)
Type IIX CSA (mm2) 618761868 323161403 <0.001 (T)
% Type I fibres* 52 (39e62) 25 (17e30) <0.001 (MW)
% Type I/II fibres* 1.5 (0e3) 3 (0e11) 0.088 (MW)
% Type II fibres 47614 69615 <0.001 (T)
% Type IIA fibres 44613 60615 0.002 (T)
% Type IIX fibres* 2.6 (0e4.0) 8.9 (3.0e13.0) 0.006 (MW)
Values are mean6SEM for normally distributed data or median (IQR) for non-normally
distributed data.
p values were calculated by t test (normally distributed data), indicated by (T), or the
ManneWhitney test (non-normally distributed data), indicated by (MW), and are shown in
bold when p<0.05.
MHC RNAs were determined by qPCR and normalised to the expression of RPLPO in the
same samples as described in the online supplement.
*Not normally distributed.
BMI, body mass index; CSA, cross-sectional area; FFMI, fat-free mass index; FEV1, forced
expiratory volume in 1 s; MVC, maximal voluntary contraction; MI, movement intensity; Mt,
movement time; PaO2, arterial oxygen tension; PaCO2, arterial carbon dioxide tension; pred,
predicted; RV, residual volume; TLC, total lung capacity; TLCO, transfer factor of the lung for
carbon monoxide; TwQ, twitch force in the quadriceps.
Figure 2 miRNA expression is markedly different in patients with
chronic obstructive pulmonary disease (COPD) compared with matched
controls. The expression of miRNAs was determined by qPCR and
normalised to the expression of 5S RNA in the same sample, as
described in the Methods section. The heat map shows the expression
of miRNAs in each sample organised by hierarchical clustering in which
the expression of each miRNA was given equal weighting. This analysis
shows clear separation of the majority of patients (closed circles) from
the control group (open circles).
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clustering (ﬁgure 2) and PCA of miRNA expression identiﬁed
a distinct proﬁle for the patients compared with the controls
(PCA, p<0.0001, ﬁgure 3B), primarily associated with an
approximate 2.5-fold reduction in the expression of miR-1
(p¼0.01(T), ﬁgure 3D and ﬁgure 4) in patients compared with
controls, but there was no change in the expression of miR-133
(ﬁgure 4). Differences in the expression of miR-208 and miR-499
contributed to the observed difference in the miRNA expression
pattern (ﬁgure 3D), although taken alone these did not reach
statistical signiﬁcance (miR-208, p¼0.099, miR-499, p¼0.142(T),
ﬁgure 4). Hierarchical clustering of the expression patterns of
individual miRNAs within the samples showed that miR-1,
miR-133 and miR-206 formed a cluster consistent with their
expression as bicistronic RNAs from the miR-1/miR-133
and miR-206/miR-133 genes, providing validation of our
methodology.
Comparison of the expression of the miRNAs with the
physiological data showed that miR-1 was negatively correlated
with smoking history (r¼0.39, p¼0.007) but positively asso-
ciated with FEV1 (r¼0.34, p¼0.022), FFMI (r¼0.33, p¼0.025),
6MW (r¼0.33, p¼0.026) and MVC/BMI (r¼0.29, p¼0.049). Like
miR-1, miR-499 was positively associated with FFMI (r¼0.37,
p¼0.012) and negatively with smoking history (r¼0.33,
p¼0.027). miR-133 and miR-206 were negatively associated
with physical activity (movement intensity; miR-133: r¼0.30,
p¼0.057; miR-206: r¼0.35, p¼0.023 and locomotion time;
miR-133: r¼0.35, p¼0.027; miR-206: r¼0.34, p¼0.029).
The association of the miRNAs with different physiological
characteristics is shown in ﬁgure 5A. Associations with p<0.05
were only present if both the control and patient groups were
combined; this feature may result from a lack of power but also
raises the possibility that disease is an important component of
the difference.
Comparison of miRNA expression with the muscle charac-
teristics showed that miR-1 was positively correlated with the
percentage of type I ﬁbres (r¼0.33, p¼0.029) and miR-499
showed a trend towards association with percentage of type I
ﬁbres (r¼0.28, p¼0.063). None of the other miRNAs was
associated with muscle ﬁbre characteristics (ﬁgure 5B).
Expression of SRF, MRTF-A, MRTF-B
To investigate the SRF system we analysed the expression of
SRF and two SRF co-activators (MRTF-A and MRTF-B) by
qPCR. Mean SRF mRNAwas not signiﬁcantly different between
the groups (COPD 3.42 (IQR 2.49e3.63) AU, n¼19; controls
3.31 (IQR 3.22e3.89) AU, n¼16, p¼0.185 (MW), ﬁgure 6A).
MRTF-A and MRTF-B mRNA levels were signiﬁcantly lower in
patients (3.73 (IQR 3.48e3.87) AU and 3.9460.394 AU respec-
tively, n¼25) than in controls (3.85 (IQR 372e4.22) AU,
p¼0.028 (MW), ﬁgure 6B and 4.4260.634 AU, p¼0.011 (T)
respectively, n¼15, ﬁgure 6C). MRTF-A expression was corre-
lated with FEV1 (% predicted, r¼ 0.46, p¼0.027) and MRTF-B
was correlated with smoking history (r¼0.576, p¼0.006, not
shown). Again these associations were not present in individual
groups. To tie this reduction in MRTF expression to miR-1, we
showed that MRTFs could activate the miR-1 promoters
(ﬁgure 6D and supplementary results).
Figure 3 Principal component
analysis of the miRNA expression
pattern in patients with chronic
obstructive disease (COPD) and
controls. (A) Scatter plot comparing
PC1 and PC2 for each sample. (B)
Principal component analysis of miRNA
expression in patients and controls
shows a significant difference in the
pattern of miRNA expression between
the two groups as a difference in PC2
(p<0.0001). (C) Loading plots for PC1
showing equal contribution of the
miRNAs to this component. (D) Loading
plots for principal component analysis
identifies miR-1, miR-208 and miR-499
as the major contributors to the
separation of the two groups. Patients
are shown as closed circles and
controls are shown as open circles.
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SRF activity is also regulated by the localisation of the protein.
We therefore determined the localisation of SRF in muscle
sections from a subset of patients with COPD and controls. In
the controls, SRF was readily detectable in the nuclei of all of the
samples analysed. However, in the patients there was a reduc-
tion in nuclear staining and the appearance of nuclei with
perinuclear SRF staining (ﬁgure 7).
Reduced expression of targets of miR-1 in patients with COPD
miR-1 targets include IGF-1 and the IGF-1 receptor,25 indicating
that it should modify the activity of the IGF-1 pathway, and we
have found that phosphorylation of the kinase Akt (also known
as protein kinase B) is inversely proportional to activity in our
patient group.32 We therefore analysed the expression of IGF-1
and the activity of the IGF-1 pathway by examining the phos-
phorylation of Akt in patients and controls. IGF-1 mRNA was
increased in patients (ﬁgure 8A) and miR-1 expression
was inversely proportional to the phospho-Akt/total Akt ratio
(ﬁgure 8B, r¼0.43, p¼0.022). A trend towards this association
was present in the patients alone (r¼0.46, p¼0.053). There
were no other associations of the phospho-Akt/total Akt ratio
with any of the other miRNAs.
We also determined the expression of histone deacetylase 4
(HDAC4) mRNA and protein in an additional set of patients
with COPD and controls. This analysis showed that, while
there was no difference in the expression of HDAC4 mRNA
between patients and controls (ﬁgure 8C), HDAC4 protein was
higher in patients with COPD than in controls (ﬁgure 8D).
DISCUSSION
This study shows that the proﬁle of miRNAs in the quadriceps
of patients with COPD differs from that in controls. The data
also suggest that MRTF/SRF activity is downregulated in
patients. Together with previous animal data showing a role for
SRF and the miRNAs in the control of muscle phenotype, these
data support the hypothesis that altered miRNA expression and
reduced SRF activity contribute to COPD-associated muscle
dysfunction.
Significance of the findings
The most striking ﬁnding is the reduction in the expression of
miR-1 in patients compared with controls. miR-1 expression is
increased by SRF,19 and we show that it is increased in an SRF-
dependent manner by the MRTFs. The reduced expression of
MRTFs, as well as altered SRF localization, suggest that reduced
activity of the MRTF/SRF axis contributes to the reduction in
MHCI and miR-1 expression. Our data also indicate functional
consequences of reduced miR-1 with increased expression of
IGF-1, an inverse correlation of miR-1 with Akt phosphorylation
and increased HDAC4 protein in the patients. Whether the
observed increase in IGF-1 mRNA is a direct response to reduced
miR-1 is not clear, as miRNAs are suggested to inhibit trans-
lation in muscle rather than increase RNA degradation.13
Consistent with this suggestion, we found that patients had
normal HDAC4 mRNA levels but increased HDAC4 protein.
The interaction of miR-1 with IGF-1 signalling and HDAC4
have been documented previously.25 33e35 These observations
raise two points regarding the role of the SRF/miR-1 axis in
muscle, which are discussed separately.
miR-1 in muscle biology
miR-1 has an accepted role in skeletal muscle differentiation.
One likely effect of the reduced miR-1 observed is the increase in
HDAC4 protein. HDAC4 inhibits the activity of MEF-2 and SRF,
both of which are important regulators of MHCI expression,
providing a mechanism by which the reduction in miR-1 may
Figure 4 Expression of microRNAs in
patients with chronic obstructive
pulmonary disease (COPD) and
controls. Expression of miRNAs was
determined by qPCR and normalised to
the expression of the 5S RNA in the
same sample as described in the
Methods section. The expression of
miR-1 (A) was lower in patients than
controls but there was no significant
difference in the expression of miR-499
(B) or the other miRNAs (C) analysed.
Data are presented as log normalised
expression with the box showing
median and IQR, error bars to maximum
and minimum points. Patients are
shown as closed circles and controls
are shown as open circles. Statistical
significance was calculated by t test.
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Figure 5 Pearson correlation matrices
for miRNAs with physiological
characteristics and muscle fibre
parameters in the cohort. MicroRNA
expression was correlated with non-
muscle physiological characteristics for
all the samples (A) or with the muscle-
specific physiological and histochemical
parameters (B). The direction and
intensity of the correlation is colour-
coded according to the bar. The
miRNAs are organised in the order of
their contribution to PC2 as determined
by principal components analysis.
Correlations reaching a statistical
significance where p<0.05 are
indicated by * and the p values are
given in table S1 in the online
supplement. Characteristics were
ordered by hierarchical clustering
(figure S4 in online supplement). BMI,
body mass index; CSA, cross-sectional
area; FFMI, fat-free mass index; FEV1,
forced expiratory volume in 1 s; Lo,
locomotion; MVC, maximal voluntary
contraction; MI, movement intensity;
Mt, movement time; 6MW, 6 min walk
test; SGRQ, St George Respiratory
Questionnaire; TwQ, twitch force in the
quadriceps; Ty, type.
Figure 6 Effect of myocardin-related
transcription factors (MRTFs) on miR-1
promoter activity and the expression of
MRTF and serum response factor (SRF) in
the quadriceps muscle of patients with
chronic obstructive pulmonary disease
(COPD). Expression of MRTF-A (A),
MRTF-B (B) and SRF (C) mRNA in the
quadriceps of patients and healthy age-
matched controls was quantified by real-
time PCR and normalised to the
expression of RPLPO. Data are presented
as log normalised expressionwith the box
showing median and IQR, error bars to
maximum and minimum points. The
expression of MRTF-A and MRTF-B was
suppressed in the patients comparedwith
controls but SRF expression did not differ
significantly between groups (AU,
arbitrary units). (D) C2C12 cells were
transfected with miR-1-1, miR-1-2
promoter reporter vectors as described in
the online supplement in the presence or
absence of expression vectors for MRTF-
A and MRTF-B. Luciferase activity was
determined 24 h later. MRTF-A and
MRTF-B increased the activity of the miR-
1-1 andmiR-1-2 promoters (p<0.001) but
did not increase the activity of the delta
enhancer promoter. Data are presented as
mean6SEM. Patients are shown as
closed circles and controls are shown as
open circles. Statistical significance for
the mRNA expression was calculated by the
ManneWhitney U test.
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contribute to reduced MHCI and ﬁbre shift. The fact that miR-1
is an SRF target provides a positive feedback loop that may
contribute to the downward spiral in muscle phenotype.
HDAC4 also suppresses the expression of follistatin: reduced
miR-1 would therefore increase the activity of the myostatin
pathway and promote muscle wasting.36 These effects of miR-1
suggest a role in the maintenance of muscle phenotype and,
consistent with these suggestions, miR-1 expression was
inversely proportional to the percentage of type I muscle ﬁbres.
The reduction in miR-1 in patients, who have a lower level of
activity than controls, is different from the response to endur-
ance training in young adults.18 miR-1 has also been suggested
to inhibit the calcineurin pathway, thereby suppressing activity-
dependent MEF-2 activation.37 The activity of miRNAs is
therefore likely to be cell and context dependent.
miR-1 also inhibits the expression of IGF-1 and, consistent
with previous reports,25 we found an inverse correlation
between miR-1 and IGF-1 signalling. A similar increase in IGF-1
mRNA has previously been observed by mRNA proﬁling in
COPD.38 The increase in IGF-1 mRNA in patients likely to show
muscle wasting seems paradoxical. However, other studies have
also shown increased activity of the hypertrophy signalling
pathway in patients with COPD, which they hypothesised to be
part of a compensation pathway39 but could also result from
synthetic resistance.
MRTF/SRF and muscle gene expression
MRTF/SRF activity is widely recognised as important in the
control of muscle-speciﬁc gene expression. However, there is
limited information on changes in the MRTFs in response to
changing activity or disease. Human studies have found that
MRTF expression increases in response to physical training and
declines following a period of detraining.21 22 Previous in vitro
and animal studies are consistent with a role for these proteins
in the regulation of MHCI expression. For example, expression
of a dominant negative MRTF-B in differentiating C2C12 cells40
reduces SRF activity and MHCI expression. Similarly,
reduced SRF activity is associated with the reduction in MHCI
and increased MHCIIa and MHCIIx following hind limb
suspension in rats.41
miRNA in muscle disease
In addition to the reduction in miR-1 expression, the pattern of
miRNA expression was also different between patients and
controls, suggesting a more general change in miRNA expres-
sion. The expression of miR-133 and miR-206 were inversely
associated with daily physical activity. This change is consistent
with the observations of Nielsen et al42 and Keller et al14 who
showed that endurance training suppresses the expression of
these and other myo-miRs. The fact that we observed no
association of miR-1 and miR-499 with physical activity
suggests that factors other than daily physical activity are more
important in determining their levels in patients with COPD.
Similarly, there was a trend towards reduced miR-499 and miR-
208, miRNAs that target myostatin, expression of which is
increased in weak COPD patients.43
Limitations of the study
The conclusions drawn from this study are limited by the cross-
sectional design that only enables us to detect associations
Figure 7 Serum response factor (SRF)
localisation is altered in patients with
chronic obstructive pulmonary disease
(COPD). The localisation of SRF was
determined in sections of quadriceps
muscle from patients with COPD and
controls by immunofluorescence as
described in the online supplement.
Arrowheads show the localisation of
nuclei and the inset shows perinuclear
staining for SRF.
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between the gene expression and physiological characteristics.
Furthermore, the data are correlative and, although they high-
light potential mechanisms, they do not prove causality. It
should be noted, however, that the highlighted associations have
been demonstrated mechanistically through in vitro and in vivo
studies.
We have also proposed that patients have reduced SRF activity
but could not make direct measurements of SRF activity in our
muscle samples. However, from the reduced MRTF and
increased MHCI and miR-1 expression, together with altered
SRF localization, it seems reasonable to conclude that SRF
activity is reduced.
CONCLUSIONS
In this study we show that the expression of miRNAs is
different in the quadriceps of patients with COPD than in
control subjects. In particular, the expression of miR-1 is reduced
and is associated with changes in ﬁbre proportion, probably
leading to the observed association with muscle mass and
exercise performance. Furthermore, the expression of the MRTFs
is also suppressed in the patients and again the expression of one
of these genes is associated with disease severity. Together with
data from studies identifying the MRTFs and SRF as critical
regulators of skeletal muscle phenotype, these ﬁndings suggest
that reduced activity of the SRF pathway contributes to COPD
skeletal muscle dysfunction, in part by downregulating miR-1
expression.
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